A novel cannabinoid type 2 receptor ligand that binds to microglial and immuno cells could be a hit for neuro-inflammatory imaging, according to a study published in the August 2013 issue of Molecular Imaging and Biology.

This week, Oct. 6-12, is Nuclear Medicine and Molecular Imaging Week and the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the SNMMI Technologist Section (SNMMI-TS) are rallying the medical community to raise public awareness about the industry.

Evaluating myocardial blood flow (MBF) with stress-rest cardiac PET teases out more multivessel CAD than with cardiac PET or SPECT alone, both of which tend to underestimate severity of disease, according the proceedings of the 2013 American Society of Nuclear Cardiology (ASNC) 2013 Annual Meeting held Sept. 26-29 in Chicago.

On the heels of the final decision from CMS regarding coverage for amyloid imaging, Peter Herscovitch, MD, SNMMI 2013-2014 president elect, discussed the potential impact of the new climate of coverage in an exclusive interview with Molecular Imaging.

Sofie Biosciences, an emerging in vivo imaging diagnostics company focused on PET probes, scanners and chemistry systems,announced today that the National Institute of Health has awarded the company a grant under the Small Business Innovation Research (SBIR) program.

A tau-imaging agent has moved ahead of the pack to pick up strong signals of tau aggregates in the brain in patterns consistent with Alzheimer’s disease (AD), according a study published Sept. 18 in Neuron.

Only one amyloid PET scan will be covered to aid in the diagnosis of Alzheimer’s disease (AD), according to an official CMS decision on Friday.

At the 55th American Society for Radiation Oncology ASTRO annual meeting, Sept. 22-25 in Atlanta, Royal Philips will feature the latest innovations that address efficient and personalized radiation oncology care for patients and their clinicians.